We are the voice of the home and specialty infusion
community and the patients we serve
NHIA represents and advances the interests of organizations that provide infusion and alternate site pharmacy services and products to the entire spectrum of home-based patients. In doing so, we consider the provision of cost-effective and high quality medical care to patients undergoing infusion therapy to be of the utmost importance.
As part of the association’s efforts to advance the industry, we monitor and advocate on a range of important health care issues. We are focused on clinical and business best-practices that may be subject to legislation, regulation, accreditation, practices of health plans/third party payers, and more. Learn more about the issues impacting the home and specialty infusion field and how to use your voice to advance the industry.
NHIA submitted comments on a CMS proposed rule (CMS-1770-P) that would affect Medicare payments and coverage of COVID-19 vaccines and monoclonal antibodies (mAbs) and coding and billing requirements related to the use of single dose containers and drug waste.
Dozens of health systems, hospitals, and group purchasing organizations are calling on Congress to address Medicare beneficiary access to home infusion services and pass legislation that would increase access to home-based care, urging congressional leaders to advance the Preserving Patient Access to Home Infusion Act (S. 2652/H.R. 5067) to encourage access to home infusion therapy for Medicare beneficiaries.
Rep. Earl L. “Buddy” Carter (R-GA.), one of two pharmacists in Congress, penned an op-ed, “Four years later, Medicare policy is still failing home infusion therapy patients” recently published in The Hill. The article highlights flaws in CMS’ implementation of the Home Infusion Therapy Services benefit that is limiting access to these services.